Kingdon Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Kingdon Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$569K	Hold	1,352,106	–	–	0.06%	73
2026 Q1	$1.18M	Buy	+1,352,106	New	+$1.88M	0.13%	65
2025 Q4	–	Sell	-1,324,845	Closed	-$3.15M	–	85
2025 Q3	$3.15M	Buy	1,324,845 +640,138	+93%	+$1.94M	0.39%	69
2025 Q2	$3.8M	Buy	684,707 +194,707	+40%	+$959K	0.51%	57
2025 Q1	$2.11M	Buy	490,000 +43,000	+10%	+$286K	0.22%	62
2024 Q4	$9.56M	Sell	447,000 -50,000	-10%	-$1.04M	1.36%	36
2024 Q3	$9.35M	Hold	497,000	–	–	1.04%	46
2024 Q2	$11.3M	Hold	497,000	–	–	1.21%	31
2024 Q1	$14.6M	Buy	497,000 +143,000	+40%	+$2.54M	1.59%	20
2023 Q4	$2.79M	Buy	354,000 +50,000	+16%	+$336K	0.35%	67
2023 Q3	$2.13M	Hold	304,000	–	–	0.25%	66
2023 Q2	$4.16M	Hold	304,000	–	–	0.39%	66
2023 Q1	$5.5M	Buy	304,000 +250,000	+463%	+$4.62M	1.03%	41
2022 Q4	$261K	Hold	54,000	–	–	0.05%	48
2022 Q3	$426K	Hold	54,000	–	–	0.05%	56
2022 Q2	$1.04M	Hold	54,000	–	–	0.18%	64
2022 Q1	$1.92M	Hold	54,000	–	–	0.2%	73
2021 Q4	$4.24M	Buy	+54,000	New	+$5.05M	0.49%	51

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Kingdon Capital Management's JSPR Position: Q2 2026 in Review

Kingdon Capital Management held its Jasper Therapeutics (JSPR) position steady in Q2 2026 at 1,352,106 shares worth $569K. The position accounts for 0.06% of the portfolio, ranked #73.

Kingdon Capital Management first reported a position in JSPR in Q4 2021 and has held it in 18 quarters since. The position peaked at $14.6M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Kingdon Capital Management held 1,352,106 shares of Jasper Therapeutics worth $569K as of Q2 2026.
Kingdon Capital Management left its Jasper Therapeutics share count unchanged in Q2 2026.
Jasper Therapeutics made up 0.06% of Kingdon Capital Management's portfolio in Q2 2026, its #73 holding.
Kingdon Capital Management first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 18 quarters since.
Kingdon Capital Management's Jasper Therapeutics position peaked at $14.6M in Q1 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.